

WHAT IS EASYHALER®

A carbon neutral, multidose inspiratory flow driven, metered dose dry powder inhaler developed for the treatment of asthma and chronic obstructive pulmonary disease.¹ Easyhaler generates accurate and consistent dose delivery – even with low inhalation flows.²



**BUFOMIX
EASYHALER®**
(Budesonide/formoterol fumarate dihydrate)

**SALFLUMIX
EASYHALER®**
(Fluticasone propionate/salmeterol xinafoate)



Carbon
Neutral
Product



ASTHMA INDICATIONS: For the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations in adults and adolescents (>12 years). Bufomix Easyhaler can be used as an anti-inflammatory reliever therapy (AIR), fixed dose maintenance therapy or anti-inflammatory reliever plus maintenance therapy (MART).³

Strength	PBS Item Number	Clinical Criteria	PBS Streamlined Authority Code	Streamlined Authority 60 Days	Max Dispensed Qty	A-Flagged
200/6 Bufomix Easyhaler	14166N	Mild Asthma (AIR)	10464	NO	2	NO
	14159F	Fixed dose maintenance	10538	NO	2	NO
	14151T	Maintenance & reliever (MART)	7970	NO	2	NO
400/12 Bufomix Easyhaler	13258T	Fixed dose maintenance >18yrs	7979	NO	2	✓
	14398T	Fixed dose maintenance >18 yrs	15617	✓	4	✓

COPD INDICATION: For the symptomatic treatment of moderate to severe COPD (FEV1 ≤50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. Bufomix Easyhaler is not indicated for the initiation of bronchodilator therapy in COPD.³

Strength	PBS Item Number	Clinical Criteria	PBS Streamlined Authority Code	Streamlined Authority 60 Days	Max Dispensed Qty	A-Flagged
200/6 Bufomix Easyhaler	This strength is not PBS subsidised for the treatment of COPD					
400/12 Bufomix Easyhaler	13258T	Maintenance or symptom relief	10121	NO	2	✓
	14398T	Maintenance or symptom relief	15548	✓	4	✓

Each inhaler contains 60 actuations and includes a dose counter and protective cover. Discard 1 month after removing the inhaler from the foil bag.

For patients to receive EASYHALER, prescribe BUFOMIX EASYHALER and ✓ the box.



ASTHMA INDICATIONS: For the regular treatment of asthma, where the use of a combination product is appropriate. This may include patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids or patients who are symptomatic on current inhaled corticosteroid therapy.⁴

Strength	PBS Item Number	Clinical Criteria	PBS Streamlined Authority Code	Streamlined Authority 60 Days	Max Dispensed Qty	A-Flagged
250/50 Salflumix Easyhaler	8431R	Maintenance or symptom relief	15138	NO	1	<input checked="" type="checkbox"/>
	14449L	Maintenance or symptom relief	15693	<input checked="" type="checkbox"/>	2	<input checked="" type="checkbox"/>
500/50 Salflumix Easyhaler	8432T	Maintenance or symptom relief	15118	NO	1	<input checked="" type="checkbox"/>
	14450M	Maintenance or symptom relief	15714	<input checked="" type="checkbox"/>	2	<input checked="" type="checkbox"/>

COPD INDICATION: For the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. SALFLUMIX EASYHALER is not indicated for the initiation of bronchodilator therapy in COPD.⁴

Strength	PBS Item Number	Clinical Criteria	PBS Streamlined Authority Code	Streamlined Authority 60 Days	Max Dispensed Qty	A-Flagged
250/50 Salflumix Easyhaler	This strength is not PBS subsidised for the treatment of COPD					
500/50 Salflumix Easyhaler	8432T	Maintenance or symptom relief	10121	NO	1	<input checked="" type="checkbox"/>
	14450M	Maintenance or symptom relief	15548	<input checked="" type="checkbox"/>	2	<input checked="" type="checkbox"/>

Each inhaler contains 60 actuations and includes a dose counter and protective cover. The SALFLUMIX EASYHALER 250/50 inhaler should be discarded 1 month after first opening the foil bag. The SALFLUMIX EASYHALER 500/50 inhaler should be discarded 2 months after first opening the foil bag.

For patients to receive EASYHALER, prescribe SALFLUMIX EASYHALER and ☒ the box.



SCAN THE QR CODE TO ACCESS CLINICAL INFORMATION,
INSTRUCTIONS FOR USE OR TO ORDER A DEMO DEVICE.



References: 1. Carbon Neutral Product Certificate for Easyhaler product range. Available on request from Orion Pharma. 2. Haikarainen J, et al. Chron Respir Dis 2018;15(3):265–71. 3. Bufomix Easyhaler Product Information, July 17, 2023. 4. Salflumix Easyhaler Product Information, August 18, 2023.

PBS information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.

Before prescribing, please review the full Product Information available via the QR codes or from
<https://www.orionpharma.com.au/products/primary-care-products>



BUFOMIX
PRODUCT
INFORMATION



SALFLUMIX
PRODUCT
INFORMATION

EASYHALER® is a registered trademark of Orion Corporation Finland.
Orion Pharma, Level 24, Tower 3, 300 Barangaroo Ave Sydney NSW 2000 Australia
www.orionpharma.com.au | contactusaaustralia@orionpharma.com For medical information or to
report an adverse event PH: 1800 861 913 or EMAIL: medical.ANZ@pharmalex.com
Date of preparation; January 2025. EH_AU_2025_03

